← boardnext 2026-12next 2026-12next 2026-12-30next 2027-11-30next 2028-12
ADIL
Dizal Pharmaceuticalsdistress 6/10 · elevated risk$2.68-1%today-83% from 52w high
Lead: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$5M
Runway
0.7 yrs
Shares 1y
-90%
Price & events
-53.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
-4.1%
1W
+5.0%
1M
+71.6%
3M
-53.4%
6M
-77.7%
1Y
-91.8%
2Y
-99.8%
5Y
-99.8%
All
Overview
- Market Cap
- $5.74M
- Volume
- 3.00K
- 52 Week Range
- $1.36 – $15.75
- Total Shares
- 2.14M
- Float Shares
- 1.40M
- Short %
- 10.61%
- % Held by Insiders
- 4.32%
- % Held by Institutions
- 27.89%
- RVOL
- 0.00x
- Beta
- 1.43
Pipeline stages · 5 programs
DZD8586, R-CHOP, R-GemOx
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
DZD9008, AZD4205
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
DZD6008, Sunvozertinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Golidocitinib, Chidamide, Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GW5282 combined with Golidocitinib, Conventional CHOP regimen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 13 trials · 13 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | DZD9008, AZD4205 | Non-small Cell Lung Cancer | — | recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | DZD8586 | Diffuse Large B Cell Lymphoma | — | active not recruiting |
| 2026-12-30 Estimated 50% readout ~2027-01-29 | Phase 1 | DZD6008 | Nonsmall-cell Lung Cancer | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 1/2 | DZD6008, Pemetrexed, Carboplatin | Non Small Cell Lung Cancer | — | recruiting |
| 2027-07 Estimated 50% readout ~2027-08-15 | Phase 2 | DZD8586 dose level 1, DZD8586 dose level 2, DZD8586 dose level 3 | Immune Thrombocytopenia (ITP) | — | recruiting |
Show all 13 trials · 8 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 2 | DZD8586 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | recruiting |
| 2027-09 Estimated 50% readout ~2027-10-01 | Phase 1 | DZD6008, Sunvozertinib | Non Small Cell Lung Cancer | — | recruiting |
| 2027-11-30 Estimated 50% readout ~2028-02-13 | Phase 3 | Golidocitinib, Chidamide, Gemcitabine | Peripheral T-cell Lymphoma | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-01-15 | Phase 1/2 | GW5282 | Advanced Solid Tumors | — | recruiting |
| 2029-01 Estimated 50% readout ~2029-03-17 | Phase 3 | DZD8586, Bendamustine, Idelalisib | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | recruiting |
| 2029-09 Estimated 50% readout ~2029-10-16 | Phase 1/2 | GW5282 combined with Golidocitinib, Conventional CHOP regimen | T-cell Lymphomas | — | recruiting |
| 2029-12 Estimated 50% readout ~2030-01-15 | Phase 2 | DZD8586, Venetoclax | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | recruiting |
| 2030-10 Estimated 50% readout ~2030-11-15 | Phase 1/2 | DZD8586, R-CHOP, R-GemOx | Diffuse Large B-Cell Lymphoma | — | recruiting |
Catalyst news & presentations · 3
- 2026-06-11partnershipAdial merged with Azora Therapeutics, issuing stock and assuming optionsSEC 8-K
- 2026-03-03partnershipAD04 · Exclusive collaboration framework with Molteni Farmaceutici for European commercialization, subject to definitive agreement.SEC 8-K
- 2025-09-16fda agreementAD04 · FDA confirmed primary endpoint: zero heavy drinking days during months 5 and 6SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $7 (+162% upside) · 2 analysts
- 2026-06-15LUCID CAPITAL MARKETSBuy
- 2025-09-30Maxim GroupHold → Buy
- 2024-11-14Rodman & RenshawBuy
Competitors — Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recent news
- 2026-07-21Adial Pharmaceuticals (ADIL) Edges Higher as Shares Test Key Resistance Zone - BPI Bull Confirmed - dars.gov.et
- 2026-07-20Adial Pharmaceuticals (ADIL) Slides 3.57%: Testing Key Support Near $2.56 - Accumulation Line - dars.gov.et
- 2026-07-17Form 4 Adial Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com South Africa
- 2026-07-16Coastlands Capital buys $8,690 of Adial Pharmaceuticals stock - Investing.com
- 2026-07-16Coastlands Capital (NASDAQ: ADIL) buys 3,233 ADIAL shares in open market - Stock Titan
- 2026-07-16Coastlands Capital LP reports $8,689 Adial Pharmaceuticals common share purchase - Bitget
- 2026-07-14AstraZeneca licenses Lung cancer drug from China’s Dizal Pharma for up to $1.5 Bn - ETPharma.com
- 2026-07-1310% owner Coastlands Capital buys $32,637 in Adial Pharmaceuticals - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.